Welcome to our dedicated page for GRI Bio news (Ticker: GRI), a resource for investors and traders seeking the latest updates and insights on GRI Bio stock.
GRI Bio Inc (GRI) is a clinical-stage biotechnology pioneer advancing novel NKT cell-targeted therapies for inflammatory and autoimmune disorders. This dedicated news hub provides investors and industry stakeholders with essential updates on therapeutic developments, financial disclosures, and strategic milestones.
Access timely reports on GRI-0621 (oral inhibitor for liver disease/dermatology) and GRI-0803 (autoimmune candidate), including clinical trial progress, regulatory filings, and peer-reviewed research. Our curated collection features press releases, earnings call transcripts, and partnership announcements directly from the company and verified sources.
Key coverage areas include phase trial results, intellectual property updates, executive leadership changes, and scientific conference presentations. Bookmark this page to monitor GRI Bio's progress in developing oral therapies that modulate immune responses through its proprietary NKT cell platform.
GRI Bio announced positive preclinical data for its lead program GRI-0621 in treating Idiopathic Pulmonary Fibrosis (IPF). The data, presented at the 2024 ATS International Conference, showed that GRI-0621 significantly reduced fibrosis and lung inflammation in a mouse model by inhibiting type 1 invariant Natural Killer T (iNKT) cell activity. The company is advancing to a Phase 2a biomarker study, with interim data expected in Q3 2024 and topline results in Q4 2024. This study will evaluate the safety, tolerability, and biomarker effects of GRI-0621 in IPF patients.
GRI-0621's mechanism involves inhibiting iNKT cells, which are pivotal in the early stages of fibrotic disease. Existing IPF treatments are and come with significant side effects, making GRI-0621 a promising candidate. GRI Bio aims to leverage the 505(b)(2) regulatory pathway to accelerate the drug's development.
GRI Bio, a biotechnology company listed on NASDAQ under the ticker GRI, will present at Alliance Global Partner’s 2024 Healthcare Company Showcase. The event is scheduled for May 21, 2024, at 2:40 PM ET. The company specializes in developing Natural Killer T (NKT) cell modulators to treat inflammatory, fibrotic, and autoimmune diseases. Marc Hertz, PhD, CEO of GRI Bio, will participate in a live webcast fireside chat. This event can be accessed through the Investors section on GRI Bio's website.
GRI Bio, Inc. reported its first quarter financial results for 2024, highlighting the progress of their lead programs GRI-0621 for Idiopathic Pulmonary Fibrosis and GRI-0803 for Systemic Lupus Erythematosus. The company is focused on advancing innovative NKT cell modulators for various diseases. The financial results showed a net loss of $1.9 million, with research and development expenses increasing compared to the previous year. GRI Bio closed a public offering in February 2024, raising $5.5 million to support ongoing operations.
GRI Bio, Inc. (NASDAQ: GRI) announced that its abstracts have been accepted for presentation at the 14th International Congress on Autoimmunity. The company will discuss innovative treatments for inflammatory, fibrotic, and autoimmune diseases, with presentations by Chief Scientific Officer, Vipin Kumar Chaturvedi. The event will take place in Ljubljana, Slovenia on May 17-20, 2024.
FAQ
What is the current stock price of GRI Bio (GRI)?
What is the market cap of GRI Bio (GRI)?
